First patients dosed in Bekinda IBS-D trial
The first patients have been dosed in a Phase II clinical study with RedHill Biopharma’s Bekinda 12 mg for diarrhoea-predominant irritable bowel syndrome (IBS-D).
Click on this link for more information.
top of page
bottom of page